Shares in Harvard Bioscience fell 8.8 percent for the five-day trading period ended Tuesday, leading all decliners in the BCW Index. Last week, Harvard Bio reported a fourth-quarter loss as investors and customers continue to wait for the sale of the firm's capital equipment business (see briefs). Bio-Rad's shares posted the biggest gain, rising 4 percent for the week.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.